I. Láng

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

I. Láng, A. Llombart-Cussac, N. Sanders, 2012, Investigational New Drugs.

Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome.

I. Çelik, C. Köhne, G. Folprecht, 2010 .

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

R. Gelber, C. Geyer, N. Wolmark, 2017, Annals of Surgical Oncology.

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

R. Finn, T. Pintér, J. Crown, 2012 .

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

E. Hitre, I. Láng, É. Remenár, 2013, British Journal of Cancer.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

R. Greil, G. Steger, M. Inbar, 2012, European journal of cancer.

Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia

A. Szász, I. Láng, T. Nagy, 2012, Pathology & Oncology Research.

Effect of genetic predisposition on the risk of gallbladder cancer in Hungary.

I. Láng, Y. Ajioka, Kazutoshi Nakamura, 2008, Asian Pacific journal of cancer prevention : APJCP.

Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours

I. Láng, Haihong Shi, A. Płotka, 2019, British journal of clinical pharmacology.

Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015.

E. Van Cutsem, I. Láng, J. Hartmann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

M. Beksac, I. Láng, K. Krzemieniecki, 2013, Wiener klinische Wochenschrift.

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

R. Finn, Marcus Schmidt, I. Bondarenko, 2014 .

S. Servitja, I. Láng, M. Margelí, 2021, European Journal of Cancer.

Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial

A. Giobbie-Hurder, P. Neven, R. Gelber, 2020, Cancer.

Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

A. Giobbie-Hurder, P. Neven, R. Gelber, 2020, Breast Cancer Research and Treatment.

AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy

Tae-You Kim, I. Láng, J. Douillard, 2008 .

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

R. Finn, Marcus Schmidt, I. Bondarenko, 2017 .

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E. Perez, M. Piccart, H. Gómez, 2016, Journal of the National Cancer Institute.

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

M. Inbar, I. Láng, R. Anghel, 2015, British Journal of Cancer.

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

R. Greil, B. Melichar, M. Inbar, 2014, British Journal of Cancer.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

R. Greil, B. Melichar, G. Steger, 2013, The Lancet. Oncology.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses.

J. Ajani, G. Bodoky, M. Lichinitser, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial.

E. Van Cutsem, G. Folprecht, P. Rougier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

C. Köhne, G. Folprecht, A. Zubel, 2009 .

Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil

E. Hitre, I. Láng, V. Adleff, 2005, Pharmacogenetics & Genomics.

The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

G. D'Haens, C. Stroh, J. Zaluski, 2008 .

Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab

E. Hitre, I. Láng, V. Adleff, 2012, Pharmacogenetics and genomics.

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.

Z. Szentirmay, E. Hitre, I. Láng, 2013, European journal of cancer.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

R. Greil, B. Melichar, G. Steger, 2016, The Lancet. Oncology.

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

E. Perez, R. Gelber, S. Martino, 2014, Journal of Clinical Oncology.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Karen A Gelmon, James N Ingle, Vered Stearns, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Yan-Shen Shan, Paul Ross, Daniel Palmer, 2016, The Lancet.

Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-Sequence Study in Patients with Solid Tumors.

I. Láng, T. Taube, H. Fritsch, 2020, Clinical therapeutics.

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

P. Neven, V. Tjan-Heijnen, I. Láng, 2020, Clinical and Translational Oncology.

Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)

R. Gelber, N. Wolmark, J. Nortier, 2012 .

Abstract P4-14-01: Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis

M. Climent, A. Lluch, K. Zaman, 2019, Poster Session Abstracts.

Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).

R. Finn, Marcus Schmidt, Xin Huang, 2015 .

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

I. Láng, L. Schwartzberg, S. Chawla, 2020, Cancer medicine.

Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)

R. Gelber, J. Baselga, Bing-he Xu, 2013 .

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.

E. Hitre, I. Láng, Z. Horváth, 2013, Journal of clinical and diagnostic research : JCDR.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

P. Neven, B. Naume, I. Láng, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Xin Huang, Johannes Ettl, Marcus Schmidt, 2015, The Lancet. Oncology.

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

E. Van Cutsem, F. Ciardiello, C. Köhne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

B. Melichar, C. Singer, I. Láng, 2016, BMC Cancer.

The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.

U. Vogel, B. Vainer, E. Hitre, 2011, Pharmacogenomics.

New drug development

O. S. Zhukova, Guy Jerusalem, Robert Millham, 2012 .

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

Marion Procter, Thomas Suter, R. Gelber, 2017, The New England journal of medicine.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

R. Gelber, D. Cameron, M. Piccart-Gebhart, 2013, The Lancet. Oncology.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

R. Gelber, A. Goldhirsch, G. Pruneri, 2016, Breast Cancer Research and Treatment.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

A. Giobbie-Hurder, R. Gelber, T. Ahern, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Sung-Bae Kim, C. Geyer, J. Bonneterre, 2013, European journal of cancer.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Sabine Tejpar, István Láng, Gunnar Folprecht, 2008 .

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

E. Hitre, T. Pintér, I. Láng, 2018, Pathology & Oncology Research.

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

R. Gelber, J. Baselga, T. Hickish, 2019, European journal of cancer.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

R. Gelber, M. Piccart, J. Baselga, 2018, Journal of the National Cancer Institute.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

J. Ajani, G. Bodoky, M. Lichinitser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Modern pharmacological therapy of breast cancer].

E. Hitre, I. Láng, Z. Horváth, 2012, Orvosi hetilap.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

R. Gelber, C. Geyer, N. Wolmark, 2014, The Lancet. Oncology.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

A. Giobbie-Hurder, J. Forbes, P. Neven, 2013, Breast Cancer Research and Treatment.

Significance of Histomorphology of Early Triple-Negative Breast Cancer

I. Láng, Z. Horváth, M. Kásler, 2012, Pathology & Oncology Research.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

J. Mackey, W. Eiermann, T. Pintér, 2011, The Lancet. Oncology.

A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

R. Ramlau, I. Láng, M. Liao, 2021, Cancer Chemotherapy and Pharmacology.

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

A. Tutt, A. Musolino, S. Litière, 2021, Clinical Cancer Research.

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

E. Perez, J. Baselga, A. Wolff, 2013, The oncologist.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

R. Finn, Marcus Schmidt, I. Bondarenko, 2016, Breast Cancer Research.

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Tae-You Kim, I. Láng, J. Douillard, 2011, Investigational New Drugs.

Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

S. Loi, Yi Zhang, M. Regan, 2023, Cancer Research.

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of Clinical Oncology.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

I. Láng, M. Bronchud, L. Mattano, 2019, Annals of Hematology.

Unusual Abdominal and Pelvic Tumors

E. Hitre, I. Láng, Z. Horváth, 2016 .

Case 3. Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy.

E. Hitre, I. Láng, Z. Horváth, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.

A. Giobbie-Hurder, J. Forbes, R. Paridaens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).

D. Shin, D. Cunningham, I. Láng, 2013 .

[Triple-negative breast carcinoma--rewiev of current literature].

I. Láng, Z. Horváth, N. Udvarhelyi, 2010, Magyar onkologia.

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.

J. Jassem, V. Semiglazov, R. Bell, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

R. Gelber, C. Geyer, N. Wolmark, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

J. Forbes, R. Gelber, B. Gusterson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B. Melichar, C. Singer, I. Láng, 2016, BMC Cancer.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, L. Chow, P. Goss, 2014, The oncologist.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

A. Giobbie-Hurder, J. Forbes, P. Neven, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.

R. Gelber, H. Gómez, A. Goldhirsch, 2018 .

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

R. Gelber, S. Martino, A. Goldhirsch, 2018 .

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

István Láng, A. Giobbie-Hurder, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

D. Shin, D. Cunningham, I. Láng, 2013, The Lancet. Oncology.

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

S. Loi, R. Salgado, P. Nuciforo, 2021, Journal of the National Cancer Institute.

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

K. Korski, J. Jassem, I. Láng, 2015, Oncotarget.

Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinoma

I. Láng, Z. Horváth, N. Udvarhelyi, 2015, SpringerPlus.

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

R. Gelber, H. Gómez, A. Goldhirsch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.

A. Urruticoechea, I. Láng, S. Im, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

C. Petropoulos, J. Jassem, I. Láng, 2017, Oncotarget.

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

K. Krejcy, A. Manikhas, I. Láng, 2012 .

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

M. Piccart, H. Gómez, I. Láng, 2020, British Journal of Cancer.

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

R. Finn, J. Crown, I. Láng, 2016, Current medical research and opinion.

Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - Results of a randomized, placebo-controlled double-blind multicentre trial

J. Féher, I. Láng, L. Prónai, 1997 .

S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.

C. Geyer, J. Bonneterre, J. Vermette, 2011 .

[Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].

T. Pintér, I. Láng, J. Szántó, 2003, Magyar onkologia.

The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma

G. Bodoky, I. Láng, S. Eckhardt, 2000, Cancer.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

R. Gelber, H. Gómez, A. Goldhirsch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

E. Winer, R. Gelber, S. Loi, 2022, Cancer Research.

Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT.

R. Greil, M. Inbar, I. Láng, 2013 .

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

R. Gelber, A. Goldhirsch, G. Viale, 2018, Breast Cancer Research and Treatment.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, P. Goss, Bing-he Xu, 2014, The oncologist.

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

I. Láng, Z. Horváth, A. Chan, 2018, Cancer medicine.

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

R. Greil, G. Steger, M. Inbar, 2010 .

Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.

R. Gelber, N. Wolmark, J. Nortier, 2017 .

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.

M. Gnant, G. Viale, M. Piccart-Gebhart, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[The clinical importance of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the 5-fluoropyrimidine-based therapy of metastatic colorectal tumours].

E. Hitre, I. Láng, V. Adleff, 2004, Magyar onkologia.

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.

R. Gelber, J. Baselga, Bing-he Xu, 2017 .

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab

E. Hitre, I. Láng, B. Budai, 2012, Angiogenesis.

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, B. Melichar, G. Steger, 2015 .

P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

D. Amadori, R. Finn, T. Pintér, 2011 .

Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)

M. Oestergaard, F. Puglisi, G. Romieu, 2015 .

[Pharmaceutical therapy of breast cancer].

T. Pintér, I. Láng, Z. Horváth, 2010, Magyar Onkológia.

[Changes in renal function during bisphosphonate treatment of breast cancer patients].

E. Hitre, I. Láng, Z. Horváth, 2008, Magyar Onkológia.

The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.

R. Labianca, K. Haustermans, E. Van Cutsem, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].

E. Hitre, I. Láng, 2006, Magyar onkologia.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].

I. Láng, K. Dede, A. Bursics, 2013, Magyar sebeszet.

Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.

A. Giobbie-Hurder, E. Winer, J. Forbes, 2013 .

R. Finn, Xin Huang, I. Láng, 2016, Current medical research and opinion.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER

J. Reis-Filho, M. Borad, D. Ryan, 2012 .

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Joon-Oh Park, K. Rau, C. Sternberg, 2016, The Lancet.